Matinas BioPharma Holdings Inc. (MTNB): Dana dhuwit perusahaan

Matinas BioPharma (MTNB) is developing advanced therapies for metabolic disorders using an innovative cellular delivery system. Transitioning from injections to tablets paves the way for licensing deals with industry behemoths. The company's cash balance demonstrates financial stability, with the latest figure standing at 0.00. The business is currently implementing automated molecule screening and software robots for clinical data analysis.
Rincian analitis lan laporan data perusahaan matinasbiopharma.com (MTNB)

Developing oral formulations for complex drugs requires significant R&D capital expenditures. This indicator captures the total volume of liquid assets and equivalents available to Matinas BioPharma (MTNB) for operational activities. By analyzing changes in cash holdings, an investor assesses the company's financial runway. A sufficient reserve minimizes the risk of equity dilution during recapitalization. A stable cash balance confirms the business's ability to sustain its technological cycle.